Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Application of pharmacogenetics: UGT1A1*28 and nilotinib-induced unconjugated hyperbilirubinaemia in a patient with chronic myeloid leukaemia.

Pathology - 1 Apr 2011

Chen Sammy Pak-lam, Poon Wing-tat, Mak Chloe Miu, Lam Ching-wan, Kwong Yok-lam, Chan Albert Yan-wo, Tam Sidney

Abstract excerpt

No abstract is available from the source.

Topics

Join the communities discussing this publication.

Bilirubin
Glucuronosyltransferase
Hyperbilirubinemia
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Molecular Diagnostic Techniques
Pharmacogenetics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Protein-Tyrosine Kinases

Source

Identifiers

PMID: 21436639
DOI: 10.1097/PAT.0b013e328343f0b4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Application of pharmacogenetics: UGT1A1*28 and nilotinib-induced unconjugated hyperbilirubinaemia in a patient with chronic myeloid leukaemia.PMID 21436639Read ↗

A novel pattern of uridine diphosphate glucuronosyltransferase polymorphisms associated with hyperbilirubinemia during nilotinib treatment.Semantic proximity Read ↗

UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia.Semantic proximity Read ↗

Influence of UGT1A1 6, 27, and 28 polymorphisms on nilotinib-induced hyperbilirubinemia in Japanese patients with chronic myeloid leukemia.Semantic proximity Read ↗

The clinical application of UGT1A1 pharmacogenetic testing: gene-environment interactions.Semantic proximity Read ↗

Gilbert-Meulengracht's syndrome and pharmacogenetics: is jaundice just the tip of the iceberg?Semantic proximity Read ↗

Pharmacogenetics of Gilbert's syndrome.Semantic proximity Read ↗

Precision Medicine: UGT1A1 Genotyping to Better Manage Irinotecan-Induced Toxicity.Semantic proximity Read ↗

Genetic Spectrum of UGT1A1 in Korean Patients with Unconjugated Hyperbilirubinemia.Semantic proximity Read ↗

UGT1A1 genetic analysis as a diagnostic aid for individuals with unconjugated hyperbilirubinemia.Semantic proximity Read ↗

Oncology Drug Dosing in Gilbert Syndrome Associated with UGT1A1: A Summary of the Literature.Semantic proximity Read ↗

Cabozantinib Induces Isolated Hyperbilirubinemia in Renal Cell Carcinoma Patients carrying the UGT1A1*28 Polymorphism.Semantic proximity Read ↗

Gilbert Syndrome: The <i>UGT1A1</i> *28 Promoter Polymorphism as a Biomarker of Multifactorial Diseases and Drug MetabolismSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.